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Cardiovascular disease in patients with multiple myeloma mayderive from factors unrelated to the disease (age, diabetes, dyslipi-demia, obesity, prior cardiovascular diseases), related to the dis-
ease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arterio -
venous shunting, anemia, renal dysfunction) and/or related to anti-
myeloma treatment (anthracyclines, corticosteroids, alkylating agents,
immunomodulatory drugs, proteasome inhibitors). Good knowledge of
cardiovascular events, effective dose reductions, prevention and manage-
ment of early and late cardiovascular side effects of chemotherapeutic
agents are essential in current clinical practice. Myeloma experts are
obliged to carefully balance the efficacy and toxicity of drugs for each
individual patient. This review summarizes current data and novel
insights into cardiovascular adverse events of today's anti-myeloma
treatment, focusing on carfilzomib, as a starting point for developing con-
sensus recommendations on preventing and managing cardiovascular
side effects in patients with multiple myeloma.
Introduction
Multiple myeloma (MM) is a plasma cell dyscrasia accounting for 1% of neoplas-
tic diseases. It typically affects the elderly population, with the median age at diag-
nosis being 70 years.1,2 Cardiovascular disease is one of the most frequent comor-
bidities in MM patients,3 being the main cause of death in western countries.4 Since
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ABSTRACT
the global population is aging, the prevalence of both MM
and cardiovascular disease is expected to increase in the
near future.5,6
Cardiovascular disease in MM may derive from factors
unrelated to the disease (age, diabetes, dyslipidemia, obe-
sity, history of cardiovascular diseases), or those related to
the myeloma (cardiac AL-amyloidosis, hyperviscosity,
high-output failure, arteriovenous shunting, anemia, renal
dysfunction) and/or be related to the treatment of the dis-
ease [anthracyclines, corticosteroids, alkylating agents,
immunomodulatory drugs, proteasome inhibitors, high-
dose conditioning and autologous/allogeneic stem cell
transplantation (SCT)].7 Of interest, the incidence of car-
diovascular disease has been described to be higher in
patients with MM (60.1%) than in non-MM patients
(54.5%)7 and a recent review and meta-analysis of patients
enrolled in clinical trials with carfilzomib showed that the
incidence of all grade and grades ≥3 cardiovascular adverse
events (CVAEs) was 18.1% and 8.2%, respectively.8
Although carfilzomib is one of the most cardiotoxic and,
at the same time, effective novel agents used in MM treat-
ment, it is not the only anti-myeloma drug characterized
by a high risk of CVAEs. Moreover, it is difficult to esti-
mate the actual incidence of chemotherapy-induced car-
diovascular diseases, because current data about drug-
induced cardiotoxicity were generated in clinical trials,
from which patients with severe cardiovascular comor-
bidities were excluded. However, in real-life clinical prac-
tice, MM patients may indeed suffer from cardiovascular
disease, have cardiovascular risk factors, and/or may have
already received several cardiotoxic drugs. Physicians
managing patients with MM are, therefore, obliged to
carefully balance expected drug efficacy with toxicity.
This review is published as a consensus paper by the
European Hematology Association (EHA), the European
Myeloma Network (EMN) and the Italian Society of
Arterial Hypertension (SIIA), and it aims to describe
CVAEs related to anti-myeloma treatment, especially
novel agents and the proteasome inhibitor carfilzomib.
Furthermore, the paper intends to be a starting point for
future debates on how to manage CVAEs appropriately.
At present, studies to validate recommendations on pre-
vention and management of CVAEs during MM treatment
are lacking, and overcoming this lacuna is particularly rel-
evant. Besides focusing on toxicity issues, this review also
aims to provide a more complete overview of MM treat-
ments by clarifying the efficacy and outcome advantages
associated with such treatments. Of note, this paper is not
only a review of the current literature, but it is also the
result of a thorough discussion involving a panel of EMN
clinical experts in MM and cardiology experts.
Cardiovascular toxicity of multiple myeloma
treatment
Antineoplastic therapy is frequently complicated by the
onset of CVAEs, which in turn may increase treatment-
related morbidity and mortality.9 Cardiovascular disease
or events are among the most frequent adverse events dur-
ing chemotherapy, leading to the concept of cardiotoxici-
ty, which may be due to the direct effects of antineoplastic
treatment on the structure and function of the heart or
may accelerate the onset of cardiovascular disease in high-
risk patients with predisposing cardiovascular risks.10
Cardiovascular complications of antineoplastic therapy
may be acute, subacute or chronic and can be classified
depending on the type of damage,11 the organ structure or
function targeted by the damage,10 or the drug responsible
for the damage.12 Depending on the damage, two types of
cardiotoxicity have been described: type I and type II. In
type I cardiotoxicity, mostly associated with traditional
anticancer therapies, there is irreversible destruction of
myocytes, leading to congestive heart failure. Type II car-
diotoxicity may involve a reversible loss of cardiac con-
tractility and is mainly caused by new targeted therapies,
such as vascular endothelial growth factor inhibitors and
tyrosine kinase inhibitors.11
With regards to the organ structure or function that is
the target of the damage, the classification of cardiovascu-
lar chemotherapy-induced complications recognizes
myocardial dysfunction and heart failure, coronary artery
disease and myocardial ischemia, arrhythmias, hyperten-
sion, thromboembolic disease, peripheral vascular disease
and stroke, pulmonary hypertension, valvular diseases
and pericardial complications.12 In MM, drug-related car-
diotoxicity may be caused by chemotherapeutic agents or
by new targeted therapies, such as immunomodulatory
drugs (thalidomide, lenalidomide, pomalidomide) and
proteasome inhibitors (bortezomib, ixazomib, carfil-
zomib).
Cardiovascular toxicity induced by chemotherapy 
Myocardial dysfunction and heart failure are common
side effects of chemotherapy and may appear early dur-
ing antineoplastic treatment or years thereafter. The risk
of heart failure is increased in elderly patients with car-
diovascular risks. Anthracyclines and alkylating agents
are associated with direct cytotoxic cardiac injury.
Cardiac damage induced by anthracyclines involves
myocyte cell membrane injury by oxygen free radicals
and lipid peroxidation, leading to oxidative stress10 and
reduced cardiac contractility. In <1% of patients the
effects may be manifested acutely (as supraventricular
arrhythmia, transient left ventricular dysfunction or elec-
trocardiographic changes). More commonly, the manifes-
tations occur early within the first year of treatment
[decline in left ventricular ejection fraction (LVEF)] or late
(chronic heart failure). Cardiotoxic effects are dose-
dependent and increased in patients with pre-existing car-
diovascular diseases and in elderly patients.
Cardiotoxicity is amplified by combination treatment,
such as with alkylating or antimicrotubule agents,
immuno- and targeted drugs. Cyclophosphamide induces
heart failure in 7-28% of cases,9 although mainly in rela-
tion to high doses before autologous SCT. The mecha-
nism of damage may be direct endothelial injury, extrava-
sation of toxic metabolites with interstitial hemorrhage,
edema and structural damage to cardiomyocytes.
Anthracyclines and alkylating agents may induce arrhyth-
mias through direct cardiotoxicity, cardiac ischemia or
metabolic changes caused by the chemotherapy.13
Moreover, all cancers lead to a prothrombotic state,
release of pro-angiogenic cytokines and drug-induced
hepatotoxicity, which may contribute further to throm-
boembolism. Thromboembolic risks are particularly high
in patients with other predisposing factors, in those with
disseminated tumors and in those with hematologic neo-
plasms, in particular MM.14 Arterial thromboembolism is
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a rare event and may occur in patients receiving anthracy-
clines. Venous thromboembolism is frequent, occurring
in 15-20% of patients with MM.10 Anthracyclines and
cyclophosphamide may also cause acute pericarditis,11
and high doses of alkylating agents have been associated
with pulmonary veno-occlusive disease.10
Cardiovascular toxicity induced by new targeted 
therapies, such as immunomodulatory drugs
Immunomodulatory drugs may induce arrhythmias,
such as bradycardia and atrioventricular block. The brady-
cardia and heart block may be caused by the antineoplas-
tic drugs themselves, age-related fibrosis or AL-amyloido-
sis. Thalidomide is associated with sinus bradycardia in
5% of patients. Sinus bradycardia can lead to syncope and
may require placement of a pacemaker.15 Immuno -
modulatory drugs are characterized by an increased risk of
thromboembolic events. The mechanisms underlying this
phenomenon are direct damage to endothelial cells,
increased platelet aggregation and higher von Willebrand
factor serum levels. In the absence of thromboprophylax-
is, the risk of venous thromboembolism is 1.3 and 4.1 per
100 patient-cycles in newly diagnosed patients receiving
thalidomide alone and in combination with dexametha-
sone, respectively. The corresponding risk at relapse is 0.4
and 0.8 per 100 patient-cycles and it increased to 6.7 in
patients treated with thalidomide, dexamethasone and
doxorubicin.16 In the absence of thromboprophylaxis, the
risk of venous thromboembolism is 0.8 and 0.7 per 100
patient-cycles in newly diagnosed and relapsed patients,
respectively, receiving lenalidomide and dexamethasone.
Venous thromboembolism may be fatal if complicated by
pulmonary embolism. Adequate prophylaxis, which is
based on risk evaluation, is therefore mandatory. Risk fac-
tors can be related to characteristics of the patient (age,
obesity, history of venous thromboembolism, central-
venous catheter, comorbidities – such as diabetes, infec-
tions, cardiac diseases –, surgical procedures – including
vertebroplasty and kyophoplasty –, and inherited throm-
bophilia); related to the myeloma (diagnosis per se, hyper-
viscosity) and related to therapy (high-dose dexametha-
sone, doxorubicin, or multi-agent chemotherapy).
Prophylaxis in low-risk patients (≤1 patient/myeloma-
related risk factor) consists of aspirin 100 mg, unless con-
traindicated. If more than one risk factor is present, low
molecular weight heparin or full-dose warfarin should be
used and continued for at least 4 months; subsequently,
switching to aspirin may be an option.17,18 New oral anti-
coagulants are increasingly being considered, although
these drugs have not been systematically studied in
myeloma yet. Specific recommendations cannot, there-
fore, be made as yet.19 Recently, a pilot study with the
novel oral anticoagulation agent apixaban was conducted
to evaluate the feasibility of venous thrombo-prophylaxis
in 104 patients with MM, during treatment with
immunomodulatory drugs. Results were encouraging but
further evaluation is needed.
Cardiovascular toxicity of proteasome inhibitors 
The metabolism of cellular proteins has a pivotal role in
regulating cell function and homeostasis. Intracellular pro-
tein degradation is mainly regulated by the ubiquitin-pro-
teasome pathway, which acts on proteins involved in cell
cycle functions, apoptosis, transcription and DNA repair.20
Proteins are tagged by ubiquitin and recognized by the
26S proteasome complex, which degrades proteins into
small peptides.21
If proteasome activity is altered, cells stop growing and
undergo apoptosis at an increased rate because of an
increasingly aberrant proteome.22 In several cancers, neo-
plastic cells are more sensitive than untransformed cells to
proteasome inhibition. Based on this evidence, protea-
some inhibitors therefore represent a highly relevant ther-
apeutic strategy in MM treatment.
The pathophysiology of the cardiotoxicity induced by
proteasome inhibitors is not entirely clear. One mecha-
nism could be the inhibition of sarcomeric protein
turnover, resulting in myocyte death.23 Other hypotheses
are increased apoptosis of endothelial progenitor cells,
endothelial nitric oxide synthase dysfunction,
functional/structural abnormalities of cardiomyocytes sec-
ondary to protein accumulation due to impaired protein
degradation, inhibition of physiological NFκB activity,
potentiation of the effects of other cardiotoxic agents, sup-
pression of the adaptive/cytoprotective activity of the
ubiquitin-proteasome pathway in an underlying car-
diomyopathy, myocardial scarring and fibrosis, endoplas-
mic reticulum stress induction in cardiomyoblasts, dys-
function of cardiac mitochondria, contractile left ventricu-
lar dysfunction and/or increased smooth muscle cell apop-
tosis causing atherosclerotic plaque instability.24-29
Bortezomib
Bortezomib is a dipeptide boronic acid that inhibits the
proteolytic activity of the proteasome chymotrypsin-like
site, via the formation of a reversible interaction at the 26S
proteasome. With regards to bortezomib-related cardiotox-
icity, the information leaflet for patients contains a warning
concerning the possibility of acute development or exacer-
bation of chronic heart failure and a new onset of decreased
LVEF. There have also been isolated cases of QT-interval
prolongation, but causality has not been established.30
The incidence of all grades of cardiac dysfunction in
patients taking bortezomib shows marked variability
from 2% to 17.9%, depending on the clinical trial.9,29 In the
meta-analysis conducted by Xiao et al., the incidence of all
grades and high-grade bortezomib-related cardiotoxicity
was 3.8% and 2.3%, respectively.29 Of interest, borte-
zomib does not seem to significantly increase the risk of
all grades or high-grade cardiotoxicity, if compared with
control medications. Nevertheless, the overall incidence of
bortezomib-related cardiotoxicity of all grades was higher
in MM patients (4.3%) than in non-MM patients.29 The
main limitation of this meta-analysis was, however, that
many cardiovascular comorbidities, as well as concomi-
tant therapies, were unknown or unrecorded. Moreover,
cardiotoxicity was misreported in many studies and the
trials' treatment designs were very different, giving rises to
heterogeneity of data regarding cardiovascular effects of
bortezomib and a high probability of confounding effects
secondary to other prior treatments or clinical conditions.
In the ENDEAVOR study, patients were randomized to
receive carfilzomib and dexamethasone (Kd) or borte-
zomib and dexamethasone (Vd).31 The patients’ median
age was fairly low (65 years), with only about 15% of
patients aged ≥75 years. The incidence of CVAEs with Vd
treatment is summarized in Table 1. During treatment or
within 30 days of receiving the last study-dose, 5% of
patients in the Vd group died and cardiovascular events
were the second cause of death. Interestingly, dyspnea
S. Bringhen et al.
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was reported as a CVAE, but its etiology (cardiac, pul-
monary versus other causes) remained undetermined, so it
could be classified as either a cardiovascular or pulmonary
adverse event.
Ixazomib
ixazomib is an oral analog of bortezomib that reversibly
inhibits the chymotrypsin-like site of the 20S proteasome,
and is responsible for caspase-dependent induction of apop-
tosis and inhibition of cell cycle in MM cells. Moreover, ixa-
zomib inhibits the NFκB pathways in MM supporting cells,
thus influencing cytokines important for MM cell growth
and survival.20 Kumar et al. reported an incidence of grade
≥3 hypertension of 5% in treatment-naïve patients given
ixazomib in combination with lenalidomide and dexam-
ethasone (Rd).32 The TOURMALINE MM1 study group
analyzed the safety and efficacy profile of ixazomib in a
phase 3 trial in patients with relapsed, refractory or relapsed
and refractory MM.33 Patients received ixazomib-Rd or
placebo-Rd. The rates of serious adverse events were simi-
lar in both groups (47% and 49%), as were death rates dur-
ing the study (4% and 6%, respectively); grade 3 or higher
adverse events occurred in 74% and 69% of cases, respec-
tively. There were no differences in the incidence of heart
failure (4% in each group), arrhythmias (16% and 15%),
hypertension (6% and 5%) and myocardial ischemia (1%
and 2%, respectively). At present, there is only one case
report in which ixazomib was described as possibly respon-
sible for cardiotoxicity with a mechanism similar to that
observed with bortezomib (type I chemotherapy-induced
cardiotoxicity).34
Carfilzomib
Relapsed or refractory multiple myeloma 
This second-generation proteasome inhibitor is an irre-
versible cell-permeable tetrapeptide epoxyketone, an ana-
log of epoxomicin.35 The irreversible binding leads to the
activity of carfilzomib being more sustained than that of
bortezomib, as new proteasome subunit synthesis and
assembly are required for restoration of proteasome activ-
ity.21 Carfilzomib has been demonstrated to be more spe-
cific than bortezomib, and the irreversible carfilzomib
binding may provide better inhibition of proteasome
activity, which may overcome bortezomib-resistance.36 In
a head to head study of carfilzomib versus standard treat-
ments, bortezomib or lenalidomide, carfilzomib demon-
strated superior efficacy and was associated with
improved overall survival. Data regarding cardiac events
in MM patients receiving carfilzomib are available from
various phase 1, 2 and 3 studies, as well as retrospective
and observational analyses, in both relapsed/refractory
MM and newly diagnosed MM. Data regarding the dosing
and treatment schedules of relevant studies are reported in
Table 2. The most frequent adverse event was hyperten-
sion. In randomized clinical trials, the relative risks of all-
grade and grade ≥3 CVAEs were 1.8 and 2.2, respectively,
for patients receiving carfilzomib compared with control
patients. Carfilzomib doses of 45 mg/m2 or higher were
associated with high-grade CVAEs.8
The incidence of hypertension in patients with
relapsed/refractory MM being treated with carfilzomib
was 14.3-25% for all grades and 3-9% for grade ≥3, the
cumulative incidence of cardiac failure of any grade was 5-
9% and that of grade ≥3 was 2-6%. Corresponding cumu-
lative values for ischemic heart disease were 3-5.9% and
1.3-3.3%. The incidence of dyspnea of any grade was 15-
19.4% while that of grade ≥3 was 1-5% (Table 1). The
most frequent cardiovascular events were dyspnea and
hypertension.31,37-43
Carfilzomib has been approved in Europe for the treat-
ment of relapsed or refractory MM, in combination with
Rd or dexamethasone, based on the randomized trials
Cardiovascular safety in MM
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Table 1. Incidence (in %) of cardiovascular events in patients with relapsed/refractory multiple myeloma treated with carfilzomib in phase 2 and 3 stud-
ies
                                                                                        Hypertension                         Cardiac failure                Ischemic heart disease                    Dyspnea
                                                                          All grades         Grade ≥3          All grades      Grade ≥3         All grades        Grade ≥3        All grades Grade ≥3
Phase 3 studies                                                                                                                                                                                                                                                                           
ASPIRE37 #                                                                                                                                                                                                                                                                                    
KRd group (n=392)                                                       14.3                        4.3                          6.4                     3.8                         5.9                       3.3                      19.4              2.8
Rd group (n=389)                                                           6.9                         1.8                          4.1                     1.8                         4.6                       2.1                      14.9              1.8
ENDEAVOR31 §                                                                                                                                                                                                                                                                            
Kd group (n=463)                                                            25                           9                            <9                     <6                         <3                       <2                        28                 5
Vd group (n=456)                                                             9                            3                            <4                     <3                         <4                       <3                        13                 2
FOCUS40                                                                                                                                                                                                                                                                                      
Carfilzomib group (n=157)                                           15                           3                             5                        2                                                                                    15                 1
CS±cyclophosphamide group (n=158)                       6                            0                             1                        1                                                                                     9                  0
Phase 2 studies38 *                                                                                                                                                                                                                                                                       
Carfilzomib (n=526)                                                                                                                   7.2                     5.7                         3.4                       1.3                                              
K: carfilzomib; R: lenalidomide; d: dexamethasone; V: bortezomib; CS: corticosteroids. #In the ASPIRE study, the category of cardiac failure included (in descending order of frequency)
cardiac failure, congestive cardiac failure, pulmonary edema, hepatic congestion, cardiopulmonary failure, acute pulmonary edema, acute cardiac failure, and right ventricular failure. The
category of ischemic heart disease included (in descending order of frequency) angina pectoris, myocardial infarction, acute myocardial infarction, an increased serum creatine kinase
level, coronary artery disease, myocardial ischemia, coronary artery occlusion, an increased troponin level, an increased level of troponin T, an acute coronary syndrome, abnormal results
on a cardiac stress test, cardiomyopathy stress, unstable angina, coronary-artery stenosis, an abnormal ST-T segment on electrocardiography, and an abnormal T wave on electrocardiog-
raphy. §In the ENDEAVOR study, cardiac failure included (in descending order of frequency): cardiac failure, ejection fraction decreased, pulmonary edema, acute cardiac failure, conges-
tive cardiac failure, acute pulmonary edema, acute left ventricular failure, chronic cardiac failure, cardiopulmonary failure, hepatojugular reflex, right ventricular failure, and left ventricular
failure. Ischemic heart disease included (in descending order of frequency): angina pectoris, acute coronary syndrome, myocardial infarction, increased troponin T, coronary artery dis-
ease, increased troponin I, acute myocardial infarction, myocardial ischemia, and cardiomyopathy stress. *Phase 2 studies38 = pooled analysis of safety data from four phase 2 studies (PX-
171-003-A0, PX-171-003-A1, PX-171-004, and PX-171-005) in 526 patients with relapsed and refractory multiple myeloma treated with carfilzomib. Carfilzomib was administered intravenously
on days 1, 2, 8, 9, 15, and 16 in 28-day cycles. The planned dose regimen was 20/27 mg/m2 (starting dose of 20 mg/m2 in cycle 1 escalating to 27 mg/m2 in cycle 2) for all studies except PX-
171-005 (15/20/27 mg/m2 in cycles 1-3 n=50).
Table 2. Data from clinical trials of carfilzomib in relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma.
Study                         Phase             N. of            Regimen                                                                        Median prior       Notes
                                                     patients                                                                                                lines (range)       
Relapsed and refractory MM
ASPIRE37                               3                      396                CFZ 20 mg/m2 cycle 1 d 1 + 2, 27 mg/m2 on d 8, 9, 15, 16         2 (1–3)              ≈50% of patients received a prior ASCT 
                                                                                              cycle 2+ 27 mg/m2 on d 1, 2, 8, 9, 15, 16                                                                 with Mel200
                                                                                              R 25 mg d 1–21, D 40 mg  on d 1,8, 15, 22                                                               ≈60% previously received V, 20% lenalidomide
                                                                       396                 R 25 mg days 1–21, D 40 mg  on d 1,8, 15, 22                             2 (1–3)              
ENDEAVOR31                       3                      464                 CFZ 20 mg/m2 cycle 1 d 1 + 2, 56 mg/m2 on d 8, 9, 15, 16               
                                                                                             cycle 2+ 56 mg/m2 on d 1, 2, 8, 9, 15, 16                                     2 (1–2)
                                                                                             D 20 mg  on d 1, 2, 8, 9, 15, 16, 22, 23                                                                       
                                                                      465                 V 1.3 mg/m2 on d 1, 4, 8, 11, D 20 mg  on d 1, 2, 4, 5, 8,           2 (1–2)
                                                                                              9, 11, 12                                                                                                      
FOCUS40                               3                      157                 CFZ 20 mg/m2 cycle 1 d 1 + 2, 27 mg/m2 on d 8, 9, 15, 16       5 (3–15)             Prior antimyeloma drugs, median (range) 8 
                                                                                              cycle 2-9 27 mg/m2 on d 1, 2, 8, 9, 15, 16                                                                  (5–17)
                                                                                              cycle 10+ 27 mg/m2 on d 1, 2, 15, 16; treatment on d 8
                                                                                              and 9 was optional per the investigator’s discretion                     
                                                                      158                 P 30 mg or D 6 mg or other equivalent corticosteroid         5 (3–17)             Prior antimyeloma drugs, median (range) 8.5
                                                                                             (not to exceed 84 mg D or equivalent per 28-d cycle).                                     (4–14)
                                                                                             Patients could receive optional V 50 mg per the 
                                                                                              investigator’s discretion.                                                                      
PX-171-003-007-A038           2                       46                  CFZ 20 mg/m2 on d 1, 2, 8, 9, 15, 16; 28-d cycles                              4                    
PX-171-003-007-A138           2                      266                 CFZ 20/27 mg/m2 on d 1, 2, 8, 9, 15, 16; 28-d cycles                         4                    
PX-171-00438                         2                      164                 CFZ 20 or 27 mg/m2 on d 1, 2, 8, 9, 15, 16; 28-d cycles                    4                    
PX-171-00538                         2                       50                  CFZ 15, 20 or 27 mg/m2 on d 1, 2, 8, 9, 15, 16; 28-d cycles              4                    
CHAMPION-141                  1-2                    116                                                                                                                                                          
Phase 1                                                         27                  CFZ on d 1, 8, and 15 of 28-d cycles. 20 mg/m2 on                          1                    Median CFZ treatment duration 7.8 months
                                                                                             cycle 1, d 1 (C1D1); subsequent doses (beginning with
                                                                                             C1D8) escalated at  45, 56, 70, or 88 mg/m2 to determine MTD  
Phase 2                                                         89                  CFZ at MTD according to the same schedule as phase 1.           1
                                                                                              D 40 mg d 1, 8, 15, 22 of a 28-d cycle for the first 8 cycles 
                                                                                              and omitted on d 22 during cycle 9 and beyond.                                                  
Newly diagnosed MM                                                                                                             Median n of cycles
CLARION47,48                         3                      478                 CFZ 20 mg/m2 d 1-2 and 36 mg/m2 thereafter                                  9                    Each regimen was given as 42-day treatment 
                                                                                             M 9 mg/m2 and P 60 mg/m2 d 1-4 of each treatment 
                                                                                             cycle for 9 cycles
                                                                      477                 BTZ 1.3 mg/m2 on d 1, 4, 8, 11, 22, 25, 29, 32
                                                                                            M 9 mg/m2 and P 60 mg/m2 d 1-4 of each treatment cycle            9                    
MYELOMA XI60                                            526                 CFZ 20 mg/m2 d 1-2 and 36 mg/m2 thereafter                                                        Patients were planned to receive a minimum of
                                                                                              Cy 500 mg/m2 on d 1, 8                                                                                                 4 cycles of induction. Therapy was continued to
                                                                                              R 25mg/d, d 1-21, D weekly (40/20mg cycles 1-4/5+)                                        maximum response or intolerance. After
                                                                                             in 28-d cycles                                                                                                                induction eligible patients could undergo
                                                                                                                                                                                                                                        autologous transplant.
                                                                    1021                Cy 500 mg/m2 on d 1, 8
                                                                                           R 25 mg/d, d 1-21, D weekly (40/20 mg cycles 1-4/5+) 
                                                                                             in 28-d cycles                                                                                                                
                                                                     1021                Cy 500 mg/m2 on d 1, 8, 15
                                                                                             T 100-200 mg/d, d 1-21, D weekly (40/20 mg cycles 1-4/5+)
                                                                                              in 28-d cycles                                                                                                                
CHAMPION-249                   1b            3 (36 mg/m2)       CFZ, twice-weekly, 3 + 3 dose escalation at 36, 45, and               8                    Treatment was continued for 8 cycles or until 
                                                              3 (45mg/m2)         56 mg/m2, followed by dose expansion.                                                                 unacceptable toxicity, withdrawal of consent, or
                                                             16 (56mg/m2)        CFZ on d 1, 2, 8, 9, 15, 16 of each cycle (20 mg/m2 on                                          progressive disease.
                                                                                             d 1 + 2 of cycle 1 and the escalated dose thereafter), 
                                                                                             Cy 300 mg/m2 on d 1, 8, 15
                                                                                              D on d 1, 8, 15, 22 of each 28-day cycle.                                            
NCT0220424150                              1-2                    148                 CFZ 36 mg/m2 on d 1, 2, 8, 9, 15, 16 in NCT02204241,                     9                    After completing 9 cycles, patients received 
NCT0185711550                                                                                                               3 dose levels escalated from 45-70 mg/m2 on d 1, 8, 15 in                                 maintenance with CFZ until progression or
NCT0134678750                                                                   NCT01857115, and  on d 1, 2, 8, 9, 15, 16 in NCT01346787.                                  intolerance.
                                                                                             Cy 300 mg/m2 on d 1, 8, 15, D 40 mg 1x/week                                                         Median age: 72 (range: 55-85) years, 38 (26%) 
                                                                                                                                                                                                                                       patients were >75 years old. Median follow-up 
                                                                                                                                                                                                                                        was 21 months.
continued on the next page
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Study                         Phase            N° of            Regimen                                                                        Median prior       Notes
                                                     patients                                                                                                lines (range)       
CYKLONE61                        1-2                     64                  CFZ was-escalated to 15/20, 20/27, 20/36 and                                  4
                                                                                              20/45 mg/m2 to determine the MTD (20/36 mg/m2). 
                                                                                              CFZ on d 1, 2, 8, 9, 15, 16
                                                                                              Cy 300 mg/m2 on d 1, 8, 15
                                                                                              T 100 mg on d 1–28, D 40 mg on d 1, 8, 15, 22                                                       
Jakubowiak 201251             1-2                     53                  CFZ (20, 27, 36 mg/m2,  on d 1, 2, 8, 9, 15, 16 +d                      12 (1-25)           After cycle 4, ASCT-candidates underwent stem 
                                                                                              1, 2, 15, 16 after cycle 8)                                                                                            cell collection then continued treatment with
                                                                                              R 25 mg/d, d 1-21, D weekly (40/20 mg cycles                                                      option of ASCT. Max. planned dose (CFZ 
                                                                                              1-4/5+) in 28-d cycles                                                                                                36 mg/m2) was expanded in phase 2.
Dytfeld 201452                    1-2           23 (subset of        Dose escalation:                                                                            MTD was not established, but 
                                                            elderly patients     CFZ 20 mg/m2 for cycle 1 on d 1, 2, 8, 9, 15, 16                                                     based on efficacy and safety, in phase II
                                                             of Jakubowiak      of 28 d, and then at 20, 27, or                                                                                   CFZ dose was 36 mg/m2.13 After 24 cycles,
                                                                    2012(49)              36 mg/m2 for 7 cycles.                                                                                                patients continued single-agent maintenance 
                                                                                            Maintenance CFZ-R-D (cycles 9-24):                                          lenalidomide off protocol.
                                                                                              CFZ on d 1, 2, 15, 16.                                                                      24 (1-24)           Median age: 72 years (range: 65-81). 
                                                                                              R 25 mg on d 1–21, D on d 1, 8, 15, 22                                                                    14 patients received a median of 24 cycles (range: 
                                                                                              at 40 mg (cycles 1-4), and at 20 mg thereafter.                                                   1-24), 2 at a CFZ dose of 20 mg/m2, 4 at 27 mg/m2,
                                                                                                                                                                                                                                       and 17 at 36 mg/m2.
CARTHADEX62                      2                      111                 Dose escalation:                                                            4                   Induction was followed by stem cell harvest after
                                                                                              CFZ 20 mg/m2 on d 1, 2 then 27 mg/m2 on                                                             Cy priming (2 to 4 mg/m2) and G-CSF. Hereafter 
                                                                                              d 8, 9, 15, 16 of cycle 1 and on d 1, 2, 8, 9, 15, 16                                                  patients received high-dose M (200 mg/m2) and
                                                                                              of cycles 2 to 4.                                                                                                           ASCT followed by consolidation treatment with 4
                                                                                              T 200 mg on d 1- 28, D 40 mg on d 1, 8, 15, 22.                                                     cycles of CFZ-T-D in the same schedule except a 
                                                                                              CFZ was escalated to 20/36 mg/m2 in cohort 2,                                                   lower dose of T (50 mg).
                                                                                              to 20/45 mg/m2 in cohort 3 and to 20/56 mg/m2 in cohort 4.                              
Bringhen 201453                   2                       58                  Dose escalation:                                                            9
                                                                                             CFZ on d 1, 2, 8, 9, 15, 16 (20 mg/m2 on d 1 + 2 
                                                                                             of cycle 1 and 36 mg/m2 thereafter).
                                                                                             Cy 300 mg/m2 on d 1, 8, 15, D 40 mg on d 1, 8, 15, 22
                                                                       Maintenance:
                                                                                              CFZ 36 mg/m2 on d 1, 2, 15, 16 until progression/ intolerance.                       
Bringhen 201754                 1/2                     54                  Dose escalation:                                                             
                                                                                             CFZ on d 1, 8, 15 (20 mg/m2 on cycle 1, d 1; subsequent 
                                                                                             doses were escalated in a standard 3+3 dose-escalation         9
                                                                                             scheme at 45, 56, 70 mg/m2. In phase 2, CFZ 70 mg/m2, 
                                                                                             with same schedule as in phase 1)
                                                                                             Cy 300 mg/m2 on d 1, 8, 15, D 40 mg on d 1, 8, 15, 22. 
                                                                       Maintenance:
                                                                                              CFZ 70 mg/m2 on d 1, 15 until progression or intolerance.
Korde63                                 2                       45                  CFZ on d 1, 2, 8, 9, 15, 16 (starting dose, 20 mg/m2                        8                   ASCT-eligible patients underwent stem cell
                                                                                              on d 1 + 2 of cycle 1; target dose, 36 mg/m2 thereafter).                                 collection after 4 cycles and continued with
                                                                                              R 25 mg on d 2- 21 of cycle 1 and on d 1- 21 of cycles 2 through 8.                treatment. After 8 cycles, all patients with at 
                                                                                              D on d 1, 2, 8, 9, 15, 16, 22, 23 (20 mg for cycles 1-4 and                                   least stable disease were to receive 2 years of 
                                                                                              10 mg for cycles 5-8; D was not administered on d 1 of cycle 1).                  extended dosing with R.
FORTE55                                2                      154                 CFZ 20/3 6 mg/m2 on d 1, 2, 8, 9, 15, 16                                               4                   The first 4 cycles were followed by high-dose M
                                                                                             Cy 300 mg/m2 on d 1, 8, 15, D 20 mg on d 1, 2, 8, 9, 15, 16                                   and ASCT and consolidation with 4 CFZ-Cy-D
                                                                                                                                                                                                                                     cycles
                                                                      309                 CFZ 20/36 mg/m2 on d 1, 2, 8, 9, 15, 16                                                4                   The first 4 cycles were followed by high-dose M
                                                                                             D 20mg on d 1, 2, 8, 9, 15, 16, R 25 mg d 1-21                                                        and ASCT and consolidation with 4 CFZ-R-D 
                                                                                             cycles
CFZ: carfilzomib; R: lenalidomide; D: dexamethasone; V: bortezomib; P: prednisone; Cy: cyclophosphamide; d: day (s), MTD: maximum tolerated dose; M: melphalan; T: thalidomide; ASCT: autologous
stem cell transplantation; MM: multiple myeloma.
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ASPIRE37 and ENDEAVOR,31 and after analysis of safety
data derived from 526 patients enrolled in four phase 2
carfilzomib studies.38
In the ASPIRE study, the incidence of dyspnea was
19.4% considering all grades and 2.8% considering only
grade ≥3 events, although the origin (cardiac, infectious,
pulmonary) remained unspecified.37 There was also
increased hypertension, which was almost double in the
carfilzomib-Rd (KRd) group as compared to the Rd group
(14.3% versus 6.9% for all grades and 4% versus 2% for
grade ≥3 in the KRd and Rd groups, respectively).
However, cardiac death rates were similar in the two
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arms: four deaths with KRd (3 myocardial ischemia, 1 car-
diac failure) and four with Rd (1 myocardial ischemia, 3
cardiac failures).
The findings of the ENDEAVOR study31 were similar to
those of ASPIRE, with a 28% incidence of dyspnea of
unspecified origin and 25% of hypertension in patients
treated with Kd. In this study, there were five cardiac
deaths with Kd and six with Vd. Patients in the Kd group
showed a higher incidence of grade ≥3 CVAEs, including
hypertension, cardiac failure and dyspnea, while the inci-
dence of ischemic heart disease was similar in the two
groups. Venous thromboembolism was more common
with Kd than with Vd (deep vein thrombosis: 3.7% for all
grades and 0.9% for grade ≥3 in Kd recipients versus 0.9%
for all grades and 0.4% for grade ≥3 in Vd recipients; pul-
monary embolism: 2.6% for all grades and 1.7% for grade
≥3 in Kd recipients versus 0.9% for all grades and 0.9% for
grade ≥3 in Vd recipients). Of interest, a preplanned
prospective ENDEAVOR substudy (ECHO study) was
performed to evaluate changes from baseline in LVEF, right
ventricular function and pulmonary artery systolic pres-
sure via echocardiography.39 Patients with a LVEF ≥40%
and no evidence of New York Heart Association class III
or IV heart failure, symptomatic ischemia, uncontrolled
arrhythmias or recent myocardial ischemia were enrolled.
All patients (75 treated with Kd, 76 treated with Vd) were
assessed using two-dimensional transthoracic echocardio-
grams at baseline, every 12 weeks and at the end of treat-
ment. Notable differences between the two treatment
groups were that more patients in the Kd group were
older than 75 years: 21.3% versus 14.5% in the Vd group)
and more had a prior cardiac-related history (26.7% versus
14.5%, respectively). Patients in the Kd arm had a higher
incidence of heart failure reported by the treating physi-
cian (10.8% versus 4.1%, respectively). A history of cardiac
disorders was associated with an elevated but not statisti-
cally significant different risk of heart failure. Patients
receiving carfilzomib had a higher incidence of hyperten-
sion compared to those receiving bortezomib (20.3% ver-
sus 8.1%, respectively). Twenty-three patients (15.2%)
discontinued treatment because of adverse events; eight
due to non-fatal cardiac-related adverse events (Kd: n=6
versus Vd: n=2). The primary endpoint was a reduction in
LVEF by 24 weeks. The ECHO data were analyzed in a
blinded fashion. Among all patients in both arms, only
one (in the Vd group) had a significant reduction in LVEF
within the first 24 weeks. Six patients (3 in each group)
had significant LVEF reductions at some time during the
study, with normal LVEF being recovered in all but one.
Fourteen patients (Kd: n=8; Vd: n=6) had clinically mean-
ingful changes in echocardiograms; 79% did not meet the
echocardiographic criteria for decreased LVEF. More Kd
than Vd recipients had clinical evidence of heart failure
(n=4 versus n=0, respectively) or pulmonary hypertension
(n=4 versus n=1, respectively) based on investigator assess-
ment. Thus, heart failure and pulmonary hypertension
occurred more frequently with Kd than with Vd, although
a echocardiographically detectable significant decline in
LVEF was low in both treatment arms and occurred with
similar frequencies. The substudy found limited utility for
serial screening with echocardiograms to mitigate cardiac
risks for unselected patients receiving carfilzomib.
Another subgroup analysis of the ENDEAVOR study, con-
ducted in 109 Asian patients, showed a toxicity profile
similar to that in the general population. In the carfilzomib
arm, hypertension was reported in 26.4% of patients, dys-
pnea in 17.0%.44
The different incidence of cardiotoxicity in ENDEAVOR
and ASPIRE can be explained by comparing both study
designs. The first factor is the carfilzomib dose: there was
a higher incidence of cardiotoxicity in the ENDEAVOR
study, but carfilzomib doses were substantially higher (56
mg/m2 versus 27 mg/m2). The second issue is that nearly
20% of the patients enrolled in the ENDEAVOR trial had
a creatinine clearance <50 mL/min (and 6% of them had a
creatinine clearance <30 mL/min) and, therefore, had a
higher cardiovascular risk, while in ASPIRE only 6.3% of
patients had a creatinine clearance between 30 and 50
mL/min.45 Consequently, a side-by-side comparison of
both trials is hampered by different patient eligibility cri-
teria.
An integrated analysis of patients with advanced MM
enrolled in four phase 2 studies showed that 73.6% of
patients had a history of cardiovascular events, and 70%
had baseline cardiac risks.38 Cardiac failure (including
chronic heart failure, pulmonary edema, and decreased
LVEF) occurred in 7.2% of patients. The overall mortality
rate was the same in patients with or without cardiovas-
cular risks at baseline. CVAEs occurred in 22.1% and
14.3% of patients had hypertension (mainly grade 1–2).
Cardiac events leading to treatment discontinuation
occurred in 4.4% of patients. Cardiac adverse events did
not increase in later treatment cycles, suggesting that there
was no cumulative toxicity. Among CVAEs, arrhythmias
of any grade were observed in 13.3% of patients (grade ≥3
in 2.3%). Dyspnea was included in respiratory adverse
events and appeared in 42.2% of patients (all grades) and
was grade ≥3 in 4.9%.
Newly diagnosed multiple myeloma
Carfilzomib, alone or in combination with other drugs,
has also been investigated in newly diagnosed MM
patients in several ongoing and completed studies.46 Data
derived from these trials are very useful, because they are
not biased by possible cardiotoxic effects of previous lines
of therapy. The incidence of any grade hypertension was
9-24.7% while that of grade ≥3 was 2-10%. The incidence
of any grade dyspnea was 18.1-28.6% while that of grade
≥3 was 3.6-4.8%. The most frequent cardiovascular
events were dyspnea and hypertension (Table 3) with no
apparent correlation with carfilzomib doses, schedules or
other drug associations.
The CLARION trial compared carfilzomib, melphalan,
and prednisone (KMP) versus bortezomib, melphalan, and
prednisone (VMP) in newly diagnosed MM patients ineli-
gible for transplant.47,48 The incidence of grade ≥3 adverse
events was 74.7% versus 76.2%, respectively. Adverse
events of interest included cardiac failure (all grades:
10.8% versus 4.3%; grade ≥3: 8.2% versus 2.8%), dyspnea
(all grades: 18.1% versus 8.5%; grade ≥3: 3.6% versus
0.6%), and hypertension (all grades: 24.7% versus 8.1%;
grade ≥3: 10.1% versus 3.6%, respectively).
The CHAMPION-2 study evaluated carfilzomib with
cyclophosphamide and dexamethasone (KCd).49 One
patient in the 45 mg/m2 cohort died due to sudden cardiac
arrest, whereas no deaths occurred in the 36 or 56 mg/m2
cohorts. The authors concluded that carfilzomib adminis-
tered at a dose of 56 mg/m2 twice weekly in combination
with cyclophosphamide and dexamethasone showed
acceptable toxicity. Likewise, an integrated analysis of
S. Bringhen et al.
1428 haematologica | 2018; 103(9)
Table 3. Incidence of cardiovascular events in patients with newly diagnosed multiple myeloma treated with carfilzomib in phase 1, 2 and 3 studies.
                                     Hypertension             Cardiac                Ischemic              Dyspnea              Exertional                 DVT/PE             Arrhythmia          Aggregated
                                                                        failure                    heart                                              dyspnea                                                                           cardiac
                                                                                                    disease                                                                                                                                     failure
                                                                                                                                                                                                                                                         *
Studies                           All     Grade         All       Grade        All      Grade         All      Grade         All      Grade          All     Grade       All       Grade      All        Grade 
                                    grades     ≥3        grades       ≥3        grades     ≥3        grades     ≥3         grades     ≥3          grades     ≥3       grades       ≥3     grades       ≥3
Phase 3 studies 
CLARION47,48                                                                                                                                                                                                                                                                                                  
KMP (n=474)                 24.7        10.1            10.8           8.2              3.0           2.1             18.1         3.6                                                                                                                                           
VMP (n=470)                   8.1          3.6              4.3            2.8              1.9           1.3              8.5          0.6                                                                                                                                           
MYELOMA XI60                                                                                                                                                                                                                                                                                              
KCRd (n=526)                  0.5                               1                                                                                                                                                                              2.5                                                 
CTd (n=1021)                   0.3                               0                                                                                                                                                                              1.3
CRd (n=1021)                    1                                0                                                                                                                                                                              1.2                                                 
Phase 1/2 studies                                                                                                                                                                                                                                                                                 
Phase 1B CHAMPION 249                                   4.8            4.8                                                28.6         4.7              38.1          4.8                                                                                                       
K dose: 36 mg/m2 (n=3),  
45 mg/m2 (n=3), 56 mg/m2
(n=16) 
CYKLONE61                                                                                                                                                                                                                                                                                                    
KCTd (n=64)                      9             6                                                                                       20            3                                                       6             5                                                16               6
Jakubowiak, 201251                                                                                                                                                                                                                                                                                       
KRd (n=53)                                                                                                                                 15            4                                               11 (DVT)4(DVT)
                                                                                                                                                                                                                               6 (PE)   6 (PE)                                                               
Dytfeld, 201452                                                                                                                                                                                                                                                                                               
KRd ≥65 years  (n=23)                                                                                                                                                                                                    13                                                                   
Phase 2 studies                                                                                                                                                                                                                                                                                    
Bringhen, 201453                                                                                                                                                                                                                                                                                         
KCd  (n=58)                       9             2                 2                2                                                    7              -                                                       2             2                4                2                                 
Bringhen, 201754                                                                                                                                                                                                                                                                                           
wKCd (n=54)                    11            0               5.5            3.7                                                                                                                         3.7          1.8             1.8              0            5.5             5.5
Korde63                                                                                                                                                                                                                                                                                                          
KRd (n=45 NDMM)                        6.6                               4.4                                                                                                                          24                                                                                   
FORTE55                                                                                                                                                                                                                                                                                                          
KRd (n=309)                                     3                                                                                                                                                                                1                                                                    
KCd (n=154)                                     3                                                                                                                                                                                0                                                                    
K: carfilzomib; M: melphalan; P: prednisone; V: bortezomib; C: cyclophosphamide; d: dexamethasone; T: thalidomide; R: lenalidomide; w: weekly; DVT: deep vein thrombosis; PE: pulmonary embolism.
*Aggregated cardiac failure includes heart failure, pulmonary edema, and myocardial infarction; NDMM: newly diagnosed multiple myeloma.
Table 4. Main studies conducted on real-life patients treated with carfilzomib-based regimens.
Study                          Type of study          N. of patients                    Rate of pre-existing CV history                                                   Rate of CVAE
Atrash56                                       R                                 130                                                            54%                                                                    11.5% hospitalized for heart failure
Chari64                                         R                                 498                                  84% of non-hospitalized; 92% of                             22% had ≥1 CVAE; 5% had ≥1 hospitalization for
                                                                                                                                           hospitalized  patients                                                                                    
Rosenthal65                                 P                                  62                                        20% baseline hypertension                                       8% had cardiac SAE; 32% had hypertension
Dimopoulos66                             P                                  60                                                             28%                                                                                    11.6% had a CVAE
R: retrospective; P: prospective; N.: number; CV: cardiovascular; CVAE: cardiovascular adverse event(s); SAE: serious adverse event(s).
newly diagnosed MM patients enrolled in three phase 1/2
studies evaluated CVAEs in patients treated with KCd.50
Any-grade cardiovascular events were reported in 42% of
patients. The risk of CVAEs during treatment with carfil-
zomib was significantly higher in patients ≥75 years old
and the most important risk factor, regardless of age, was
hypertension. Grade ≥3 adverse events occurred in 30% of
patients. In patients <75 years, the most frequent grade ≥
3 adverse events were hypertension (9%) and dyspnea
(10%). In patients ≥75 years, the most frequent grade ≥3
adverse events were hypertension and pulmonary edema
(both: 13%). Thirty-four percent of patients who devel-
oped CVAEs had hypertension at baseline or developed it
during treatment compared with 14% of patients who did
not have CVAEs. The risk of cardiotoxicity was lower dur-
ing maintenance, with 22% of patients developing a car-
diovascular event of any grade. The most frequent CVAE
during maintenance was again hypertension (12%),
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regardless of age. Five cardiovascular carfilzomib-related
deaths were reported. No difference was observed in rela-
tion to different carfilzomib doses and schedules.
A phase 1/2 study in newly diagnosed MM patients
assessed carfilzomib, lenalidomide and weekly dexam-
ethasone. During induction, grade 3/4 CVAEs included
deep venous thrombosis/pulmonary embolism in 9% of
cases. Grade 3/4 dyspnea was observed only during phase
1 and within the first three cycles.51 An updated follow-up
in a subset of 23 elderly patients (≥65 years) was also per-
formed:52 during induction, non-hematologic grade 3/4
adverse events (>10%) included thromboembolic events
(13%). During maintenance, most adverse events were
grade 1/2 and did not include CVAEs. This could be par-
tially because patients reaching the maintenance phase
have deeper and longer responses to therapy, and tolerate
the treatment better.  
In a multicenter, open-label phase 2 trial of KCd in eld-
erly newly diagnosed MM patients, ineligible for autolo-
gous SCT53, cardiac adverse events of any grade occurred
during induction in 16% of patients and of grade ≥3 in 7%
and included four cardiac events (heart failure, arrhyth-
mia, myocardial ischemia and hypertension in one patient
each) and stroke, acute pulmonary edema and pulmonary
thromboembolism (also in one patient each). The safety
profile was similar in the 15 patients >75 years who
received one or more doses of KCd. As expected, no
CVAEs occurred during maintenance. Seven patients died
while on the study, one due to hypertension (related to
carfilzomib) and another due to atrial fibrillation (deemed
unrelated to carfilzomib).
A multicenter, open-label phase 1/2 trial determined the
safety and efficacy of KCd in a weekly schedule in newly
diagnosed patients aged ≥65 years who were ineligible for
autologous SCT.54 Cardiopulmonary adverse events
occurred in 9%. During induction, the incidence of CVAEs
of any grade was 24%, while the incidence of CVAEs of
grade 3–5 was 9%. Treatment-emergent serious adverse
events occurred during induction in 26% of patients and
included eight cardiac events (heart failure, pulmonary
edema, sudden death and hypertension) and one pul-
monary thromboembolism. During maintenance, any
grade hypertension occurred in 15% of cases. Grade 3-5
non-hematologic adverse events were rare except for
hypertension (10% of cases) and CVAEs (5%: 1 heart fail-
ure and 1 myocardial ischemia). Treatment-emergent seri-
ous adverse events occurred during maintenance in three
patients and included heart failure and myocardial
ischemia.
The FORTE trial compared KRd versus KCd in trans-
plant-eligible patients with newly diagnosed MM.55 No
significant differences were seen in rates of CVAEs (hyper-
tension: 7% versus 6%, cardiac adverse events: 3% versus
5%), with the exception of venous thromboembolism/
pulmonary embolism (8% versus 2%). The slightly lower
incidence of CVAEs, as compared to other studies, could
be partially explained by the fact that newly diagnosed
MM patients eligible for transplantation are fitter than
those with relapsed or refractory MM and/or patients inel-
igible for autologous SCT. 
Real-life experience
Data derived from “real-life” experience with carfil-
zomib unite more unselected patients than those treated
within clinical trials, although they do not add much to
currently available knowledge (Table 4). The most robust
data are derived from the study by Atrash et al., in 130
relapsed/refractory patients. In that study, 20% of patients
had CVAEs. A history of cardiac events was present in
54% of patients.56 Fifteen (11.5%) were hospitalized for
chronic heart failure, serious arrhythmias or pulmonary
edema. Of four patients hospitalized for arrhythmia, two
had cardiac arrests.
Conclusions
Melphalan, cyclophosphamide, and doxorubicin are fre-
quently used in the treatment of MM, especially in the
context of high-dose chemotherapy. Alkylating agents and
anthracyclines are both characterized by the potential for
cardiotoxicity. Cardiac function must be monitored care-
fully in patients taking these drugs, particularly in the
long-term, because of late onset toxicity.
Electrocardiography and transthoracic echocardiography
are useful for assessing cardiac function before high-dose
melphalan and/or anthracycline-based treatment.
Immunomodulatory drugs, especially in combination
with corticosteroids and chemotherapy, are associated
with a high frequency of thromboembolic complications.
Prophylaxis with cardio-aspirin, low molecular weight
heparin or warfarin is mandatory. The choice of the most
appropriate drug depends on the thrombotic risk. If the
probability of venous thromboembolism/pulmonary
embolism is high, low molecular weight heparin or war-
farin should be preferred. 
Cardiac adverse events are thought to be a class effect of
proteasome inhibitors because they have been reported
with bortezomib, carfilzomib and ixazomib; however,
they appear to be more frequent with carfilzomib. A
recent meta-analysis showed that the most frequent
CVAEs during treatment with carfilzomib are hyperten-
sion (all grades: 12.2%; grade ≥3: 4.3%), heart failure (all
grades: 4.1%; grade ≥3: 2.5%) and ischemic heart disease
(all grades: 1.8%; grade ≥3: 0.8%).8 The incidence of heart
failure increases up to 20-25% in patients ≥75 years of age.
Although true carfilzomib-induced cardiac failure is infre-
quent and usually reversible, MM patients are typically
elderly individuals and may frequently have cardiovascu-
lar comorbidities, thereby increasing their risk of drug-
related CVAEs.57 As found in the clinical trials described
above, age is not the only risk factor for cardiovascular
toxicity. Comorbidities, especially pre-existing hyperten-
sion or cardiovascular diseases, carfilzomib dose, infusion
time, and volume of hydration may increase the risk of
CVAEs during carfilzomib treatment.43
However, carfilzomib has been shown to prolong both
progression-free and overall survival in MM patients, and
maximizing the benefit while reducing cardiovascular
risks has become a priority in the management of these
patients. At present, there are no strategies to prevent
CVAEs that have been validated in prospective studies.
The EMN expert panel suggests, based on clinical experi-
ence, that cardiovascular risks should be assessed before
starting carfilzomib and that measures to correct modifi-
able risk factors, such as hypertension, high cholesterol
levels, hyperglycemia, tobacco use, incorrect diet, should
be started. Patients with cardiac risks may benefit from a
cardiology review prior to receiving treatment and should
be closely monitored for fluid overload. Patients receiving
S. Bringhen et al.
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antihypertensive medications may need drug adjustments
to reduce their blood pressure while receiving carfilzomib.
Regular clinical surveillance with blood pressure control is
recommended before and during treatment. In a sub-study
of the ENDEAVOR trial, the rate of hypertension was
25% in the entire cohort and 26.4% in an Asian cohort.
These rates are higher than in other studies and suggest
that particular attention is needed in patients treated with
carfilzomib 56 mg/m2 and in subjects of Asian ethnicity.
Serial monitoring of cardiac function via echocardiogra-
phy39 or cardiac biomarkers such as NT-proBNP are con-
sidered of limited value in mitigating the risk of carfil-
zomib-associated cardiac failure.58 In the event of grade 3
or 4 cardiac events, carfilzomib should be withheld until
recovery.59 Carfilzomib may be resumed at the physician’s
discretion based on a benefit/risk assessment, although
preferably at a reduced dose.
In general, the risk-benefit ratio for a drug must be con-
sidered in the context of the nature and severity of the
disease for which it is used. Dynamic, interdisciplinary
cooperation between hematologists and cardiologists is
the key to the future studies that are needed to assess
and manage cardiovascular safety in patients treated
with carfilzomib.
Cardiovascular safety in MM
haematologica | 2018; 103(9) 1431
References
1. Moreau P, San Miguel J, Ludwig. H, et al, on
behalf of the ESMO Guidelines Working
Group. Multiple myeloma: ESMO clinical
practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 2013;24(6):
vi133-vi137.
2. National Cancer Institute. SEER Stat Fact
Sheets: Myeloma. Available at:
www.seer.cancer.gov/statfacts/html/mulmy
.html. Accessed March 2016.
3. Kistler KD, Rajangam K, Faich G, Lanes S.
Cardiac event rates in patients with newly
diagnosed and relapsed multiple myeloma
in US clinical practice. Blood. 2012;102
(21):2916.
4. WHO 2016 Fact sheets-media centre.
http://www.who.int/mediacentre/fact-
sheets/fs317/en/. 
5. WHO 2016 fact files. http://www.who.int/
features/factfiles/ageing/ageing_facts/en/.
6. Benjamin EJ, Blaha MJ, Chiuve SE, et al;
American Heart Association Statistics
Committee and Stroke Statistics
Subcommittee. Heart disease and stroke sta-
tistics-2017 update: a report from the
American Heart Association. Circulation.
2017;135(10):e146-e603.
7. Kistler KD, Kalman J, Sahni G, et al.
Incidence and risk of cardiac events in
patients with previously treated multiple
myeloma versus matched patients without
multiple myeloma: an observational, retro-
spective, cohort study. Clin Lymphoma
Myeloma Leuk. 2017;17(2):89-96.
8. Waxman AJ, Clasen S, Hwang WT, et al.
Carfilzomib-associated cardiovascular
adverse events. A systematic review and
meta-analysis. JAMA Oncol. 2018;4(3):
e174519. 
9. Yeh ETH, Bickford CL. Cardiovascular com-
plications of cancer therapy: incidence,
pathogenesis, diagnosis, and management. J
Am Coll Cardiol. 2009; 53(24):2231–2247.
10. Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, et al. 2016 ESC Position Paper on
cancer treatments and cardiovascular toxici-
ty developed under the auspices of the ESC
Committee for Practice Guidelines: The
Task Force for cancer treatments and cardio-
vascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J.
2016;37(36):2768-2801.
11. Bhave M, Akhter N, Rosen ST.
Cardiovascular toxicity of biologic
agents for cancer therapy. Cancer
Network 2014. Available at
http://www.cancernetwork.com.
12. Sheppard RJ, Berger J, Sebag IA.
Cardiotoxicity of cancer therapeutics: cur-
rent issues in screening, prevention and ther-
apy. Front Pharmacol. 2013;4:19.
13. Hong RA, Limura T, Sumida KN, Eager RM.
Cardio-oncology/onco-cardiology. Clin
Cardiol. 2010;33(12):733-737.
14. Palumbo A, Rajkumar SV, Dimopoulos MA,
et al; International Myeloma Working
Group. Prevention of thalidomide- and
lenalidomide-associated thrombosis in
myeloma. Leukemia. 2008;22(2):414-423.
15. Dimopoulos MA, Eleutherakis-Papaiakovou
V. Adverse effects of thalidomide adminis-
tration in patients with neoplastic diseases.
Am J Med. 2004;117(7):508-515.
16. Carrier M, Le Gal G, Tay J, Wu C, Lee AY.
Rates of venous thromboembolism in multi-
ple myeloma patients undergoing
immunomodulatory therapy with thalido-
mide or lenalidomide: a systematic review
and meta-analysis. J Thromb Haemost.
2011;9(4):653–663.
17. Terpos E, Kleber M, Engelhardt M, et al.
European Myeloma Network guidelines for
the management of multiple myeloma-relat-
ed complications. Haematologica.
2015;100(10):1254-1266.
18. Dimopoulos MA, Leleu X, Palumbo A, et al.
Expert panel consensus statement on the
optimal use of pomalidomide in relapsed
and refractory multiple myeloma.
Leukemia. 2014;28(8):1573-1585.
19. Pegourie B, Pernod G, Karlin L, et al.
Evaluation of an oral direct anti-Xa anticoag-
ulant, apixaban, for the prevention of
venous thromboembolism in patients with
myeloma treated with IMiD* compounds: a
pilot study (MYELAXAT). J Clin Oncol.
2017;35(Suppl15):8019.
20. Kubiczkova L, Pour L, Sedlarikova L, et al.
Proteasome inhibitors-molecular basis and
current perspectives in multiple myeloma. J
Cell Mol Med. 2014;18(6):947-961.
21. Dou PQ, Zonder JA. Overview of protea-
some inhibitor-based anti-cancer therapies:
perspective on bortezomib and second gen-
eration proteasome inhibitors versus future
generation inhibitors of ubiquitin-protea-
some system. Curr Cancer Drug Targets.
2014;14(6):517-536.
22. Moreau P, Richardson PG, Cavo M, et al.
Proteasome inhibitors in multiple myeloma:
10 years later. Blood. 2012;120(5):947-959.
23. Hasinoff BB, Patel D, Wu X. Molecular
mechanism of the cardiotoxicity of the pro-
teasomal targeted drugs bortezomib and
carfilzomib. Cardiovasc Toxicol. 2017;17(3):
237-250.
24. Takamatsu H, Yamashita T, Kotani T, et al.
Ischemic heart disease associated with
bortezomib treatment combined with dex-
amethasone in a patient with multiple
myeloma. Int J Hematol. 2010;91(5):903-
906. 
25. Nowis D, M czewski M, Mackiewicz U, et
al. Cardiotoxicity of the anticancer thera-
peutic agent bortezomib. Am J Pathol.
2010;176(6):2658-2668. 
26. Hacihanefioglu A, Tarkun P, Gonullu E.
Acute severe cardiac failure in a myeloma
patient due to proteasome inhibitor borte-
zomib. Int J Hematol. 2008;88(2):219-222. 
27. Foley P, Hamilton MS, Leyva F. Myocardial
scarring following chemotherapy for multi-
ple myeloma detected using late gadolinium
hyperenhancement cardiovascular magnetic
resonance. J Cardiovasc Med. 2010;11(5):
386-388. 
28. Voortman J, Giaccone G. Severe reversible
cardiac failure after bortezomib treatment
combined with chemotherapy in a non-
small cell lung cancer patient: a case report.
BMC Cancer. 2006;6:129. 
29. Xiao Y, Yin J, Shang Z. Incidence and risk of
cardiotoxicity associated with bortezomib
in the treatment of cancer: a systematic
review and meta-analysis. Plos One.
2014;9(1):e87671.
30. http://www.ema.europa.eu/docs/en_GB/
d o c u m e n t _ l i b r a r y / E P A R _ -
_Summary_for_the_public/human/000539/
WC500048136.pdf
31. Dimopoulos M, Moreau P, Palumbo A, et al;
ENDEAVOR Investigators. Carfilzomib and
dexamethasone versus bortezomib and dex-
amethasone for patients with relapsed or
refractory multiple myeloma (ENDEAVOR):
a randomized, phase 3, open-label, multi-
centre study. Lancet Oncol. 2016;17(1):27-
38.
32. Kumar SK, Berdeja JG, Niesvizky R, et al.
Safety and tolerability of ixazomib, an oral
proteasome inhibitor, in combination with
lenalidomide and dexamethasone in
patients with previously untreated multiple
myeloma: an open-label phase 1/2 study.
Lancet Oncol. 2014;15(13):1503-1512.
33. Moreau P, Masszi T, Grzasko N, et al;
TOURMALINE-MM1 Study Group. Oral
Ixazomib, lenalidomide, and dexametha-
sone for multiple myeloma. N Engl J Med.
2016;374(17):1621-1634.
34. Jouni H, Aubry MC, Lacy MQ, et al.
Ixazomib cardiotoxicity: a possible class
effect of proteasome inhibitors. Am J
Hematol. 2017;92(2):220-221.
35. Kortuem KM, Stewart AK. Carfilzomib.
Blood. 2013;121(6):893-897.
36. Schlafer D, Shah KS, Hall Panjic E, Lonial S.
Safety of proteasome inhibitors for treat-
ment of multiple myeloma. Expert Opin
Drug Saf. 2017;16(2):167-183.
37. Stewart AK, Rajkumar SV, Dimopoulos MA,
et al; ASPIRE Investigators. Carfilzomib,
lenalidomide, and dexamethasone for
relapsed multiple myeloma. N Engl J Med.
2015;372(2):142-152.
38. Siegel D, Martin T, Nooka A, et al.
Integrated safety profile of single-agent
carfilzomib: experience from 526 patients
enrolled in 4 phase II clinical studies.
Haematologica. 2013;98(11):1753-1761.
39. Hájek R, Russell SD, Lyon A, et al. A sub-
study of the phase 3 ENDEAVOR study:
serial echocardiographic assessment of
patients with relapsed multiple myeloma
(RMM) receiving carfilzomib plus dexam-
ethasone or bortezomib plus dexametha-
sone. Haematologica. 2016;101(S1):263.
40. Hájek R, Masszi T, Petrucci MT, et al. A ran-
domized phase III study of carfilzomib vs
low-dose corticosteroids with optional
cyclophosphamide in relapsed and refracto-
ry multiple myeloma (FOCUS). Leukemia.
2017;31(1):107-114. 
41. Berenson JR, Cartmell A, Bessudo A, et al.
CHAMPION-1: a phase 1/2 study of once
weekly carfilzomib and dexamethasone for
relapsed or refractory multiple myeloma.
Blood. 2016;127(26):3360-3368.
42. Delforge M, Ludwig H. How I manage the
toxicities of myeloma drugs. Blood.
2017;129(17):2359-2367. 
43. Ludwig H, Delforge M, Facon T, et al.
Prevention and management of adverse
events of novel agents in multiple myeloma:
a consensus of the european myeloma net-
work. Leukemia. 2018 May 2. [Epub ahead
of print] 
44. Lee JH, Huang SY, Liu JH, et al. Outcomes
for Asian patients with relapsed multiple
myeloma treated with carfilzomib and dex-
amethasone Vs bortezomib and dexametha-
sone: a subgroup analysis of the phase 3
ENDEAVOR Study (NCT01568866).
Haematologica. 2016;101(S1):549-550.
45. Dimopoulos MA, Siegel D, White DJ, et al.
Superior efficacy of carfilzomib and dexam-
ethasone (Kd56) vs bortezomib and dexam-
ethasone (Vd) in multiple myeloma (MM)
patients with moderate or serious renal fail-
ure: a sobgroup analysis of the phase 3
ENDEAVOR study. Blood. 2017;130(Suppl
1):1845.
46. Sugumar D, Keller J, Vij R. Targeted treat-
ments for multiple myeloma: specific role of
carfilzomib. Pharmgenomics Pers Med.
2015;20;8:23-33. 
47. Facon T, Lee JH, Moreau P, et al. CLARION:
Phase 3 study of carfilzomib, melphalan,
prednisone vs bortezomib, melphalan, pred-
nisone in newly diagnosed multiple myelo-
ma. Clin Lymphoma Myeloma Leuk.
2017;17(Suppl):e26-e27.
48. Data available at https://www.amgen.com/
media/news-releases/2016/09/amgen-
announces-topline-results-from-phase-3-
kyprolis-carfilzomib-clarion-study-in-
newly-diagnosed-multiple-myeloma-
patients/
49. Boccia RV, Bessudo A, Agajanian R, et al. A
multicenter, open-label, phase 1b study of
carfilzomib, cyclophosphamide, and dex-
amethasone in newly diagnosed multiple
myeloma patients (CHAMPION-2). Clin
Lymphoma Myeloma Leuk. 2017;17(7):433-
437.
50. Bringhen S, Petrucci MT, Giuliani N, et al.
An integrated analysis of cardio-vascular
adverse events of carfilzomib, cyclophos-
phamide and dexamethasone in elderly
newly diagnosed myeloma patients enrolled
in 3 phase I/II trials. Blood. 2016;128(22):
3336.
51. Jakubowiak AJ, Dytfeld D, Griffith KA, et al.
A phase 1/2 study of carfilzomib in combi-
nation with lenalidomide and low-dose dex-
amethasone as a frontline treatment for mul-
tiple myeloma. Blood. 2012;120(9):1801-
1809. 
52. Dytfeld D, Jasielec J, Griffith KA, et al.
Carfilzomib, lenalidomide, and low-dose
dexamethasone in elderly patients with
newly diagnosed multiple myeloma.
Haematologica. 2014;99:e162-e164.
53. Bringhen S, Petrucci MT, Larocca A, et al.
Carfilzomib, cyclophosphamide, and dex-
amethasone in patients with newly diag-
nosed multiple myeloma: a multicenter,
phase 2 study. Blood. 2014;124(1):63-69.
54. Bringhen S, D’Agostino M, De Paoli L, et al.
Phase 1/2 study of weekly carfilzomib,
cyclophosphamide, dexamethasone in
newly diagnosed transplant-ineligible
myeloma. Leukemia. 2018;32(4):979-985.
55. Gay F, Rota Scalabrini D , Belotti A, et al.
Carfilzomib-lenalidomide-dexamethasone
vs carfilzomib-cyclophosphamide-dexam-
ethasone induction: planned interim analy-
sis of the randomized FORTE trial in newly
diagnosed multiple myeloma. J Clin Oncol.
2017;35(Suppl 15):8003. 
56. Atrash S, Tullos A, Panozzo S, et al. Cardiac
complications in relapsed and refractory
multiple myeloma patients treated with
carfilzomib. Blood Cancer J. 2015;5:e272.
57. Lenihan DJ, Potluri R, Bhandari H, Ranjan S
and Chen C. Evaluation of cardiovascular
comorbidities among patients with multiple
myeloma in the United States. Blood.
2016;128(4):479-487.
58. Rosenthal A, Luthi J, Belohlavek M, et al.
Carfilzomib and the cardiorenal system in
myeloma: an endothelial effect? Blood
Cancer J. 2016;6(1):e384.
59. Atrash S, Tullos A, Panozzo S, et al. Cardiac
complications in relapsed and refractory
multiple myeloma patients treated with
carfilzomib. Blood Cancer J. 2015;5(1):e272-
e272.
60. Pawlyn C, Davies F, Cairns D, et al.
Quadruplet vs sequential triplet induction
Therapy for myeloma patients: results of the
MYELOMA XI study. Haematologica. 2017;
102(S2):142.
61. Mikhael JR, Reeder CB, Libby EN, et al.
Phase Ib/II trial of CYKLONE (cyclophos-
phamide, carfilzomib, thalidomide and dex-
amethasone) for newly diagnosed myelo-
ma. Br J Haematol. 2015;169(2):219-227.
62. Wester R, van der Holt B, Asselbergs E, et al.
Phase 2 study of carfilzomib, thalidomide,
and low-dose dexamethasone as
induction/consolidation in newly diag-
nosed, transplant eligible patients with mul-
tiple myeloma, the carthadex trial. Blood.
2016;128(22):1141. 
63 Korde N, Roschewski M, Zingone A, et al.
Treatment with carfilzomib-lenalidomide-
dexamethasone with lenalidomide exten-
sion in patients with smoldering or newly
diagnosed multiple myeloma. JAMA Oncol.
2015;1(6):746-754.
64. Chari A, Aggarwal S, Mezzi K, et al. Cardiac
events in real-world multiple myeloma
patients treated with carfilzomib: a retro-
spective claims database analysis. Blood.
2016;128(22):3319.
65. Rosenthal AC, Luthi J, Belohlavek M, et al.
The cardiovascular impact of carfilzomib in
multiple myeloma. Blood. 2014;124(21):
4748.
66. Dimopoulos MA, Roussou M,
Gavriatopoulou M, et al. Cardiac and renal
complications of carfilzomib in patients
with multiple myeloma. Blood Adv.
2017;1(7):449-454.
S. Bringhen et al.
1432 haematologica | 2018; 103(9)
